ReviewBritish journal of pharmacology2018
G protein-coupled receptors not currently in the spotlight: free fatty acid receptor 2 and GPR35.
Review in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Reprogramming aerobic metabolism mitigates Streptococcus pyogenes tissue damage in a mouse necrotizing skin infection model.Nature communications · 2025Article
- Article
- Article
- Kynurenine Pathway Metabolites as Potential Biomarkers in Chronic Pain.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Protease-activated receptor-2 promotes osteogenesis in skeletal mesenchymal stem cells at the expense of adipogenesis: Involvement of interleukin-6.Bone reports · 2021Article
- Modulation of Short-Chain Fatty Acids as Potential Therapy Method for Type 2 Diabetes Mellitus.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2021Review
- Review
- Lodoxamide Attenuates Hepatic Fibrosis in Mice: Involvement of GPR35Biomolecules & therapeutics · 2020Article
- A Recent Achievement In the Discovery and Development of Novel Targets for the Treatment of Type-2 Diabetes Mellitus.Journal of experimental pharmacology · 2020Review
- UEG Week 2019 Oral Presentations.United European gastroenterology journal · 2019Article
- GPCRomics: An Approach to Discover GPCR Drug Targets.Trends in pharmacological sciences · 2019Review
- Chemogenetics defines receptor-mediated functions of short chain free fatty acids.Nature chemical biology · 2019Article
- GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump.Science signaling · 2019Article
- G protein-coupled receptors not currently in the spotlight: free fatty acid receptor 2 and GPR35.British journal of pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
It is widely appreciated that G protein-coupled receptors have been the most successfully exploited class of targets for the development of small molecule medicines. Despite this, to date, less than 15% of the non-olfactory G protein-coupled receptors in the human genome are the targets of a clinically used medicine. In many cases, this is likely to reflect a lack of understanding of the basic underpinning biology of many G protein-coupled receptors that are not currently in the spotlight, as well as a paucity of pharmacological tool compounds and appropriate animal models to test in vivo function of such G protein-coupled receptors in both normal physiology and in the context of disease. 'Open Innovation' arrangements, in which pharmaceutical companies and public-private partnerships provide wider access to tool compounds identified from ligand screening programmes, alongside enhanced medicinal chemistry support to convert such screening 'hits' into useful 'tool' compounds will provide important routes to improved understanding. However, in parallel, novel approaches to define and fully appreciate the selectivity and mode of action of such tool compounds, as well as better understanding of potential species orthologue variability in the pharmacology and/or signalling profile of a wide range of currently poorly understood and understudied G protein-coupled receptors, will be vital to fully exploit the therapeutic potential of this large target class. I consider these themes using as exemplars two G protein-coupled receptors, free fatty acid receptor 2 and GPR35.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.